OliX Pharmaceuticals KRX:226950KOSDAQ
올릭스 · Korean news coverage and regulatory filings, organized.
Articles, 24h2
Articles, 7 days4
DART filings, 7 days0
Articles tracked4since Sep 11
In Q2 2026, OliX Pharmaceuticals reported an operating loss of ₩14.0bn. OliX Pharmaceuticals (올릭스) appeared in 4 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 14 with 4 articles. It was most often mentioned alongside Sky Labs and Chong Kun Dang Pharmaceutical.
OliX Pharmaceuticals quarterly results consolidated, KRW
| Quarter | Operating profit | Net income |
|---|---|---|
| Q2 2026 | −₩14.0bn | −₩11.0bn |
| Q1 2026 | −₩10.8bn | −₩9.8bn |
| Q4 2025 derived | −₩8.5bn | ₩15.4bn |
| Q3 2025 | −₩8.3bn | −₩8.7bn |
| Q2 2025 | −₩5.0bn | −₩9.2bn |
| Q1 2025 | −₩8.2bn | −₩13.3bn |
| Q4 2024 derived | −₩7.6bn | −₩12.2bn |
| Q3 2024 | −₩9.4bn | −₩10.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
OliX Pharmaceuticals top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
